This article is a correction to:
C-reactive protein isoforms as prognostic markers of COVID-19 severity
Blanca Molins1*
Marc Figueras-Roca1,2
Oliver Valero3Victor Llorens1,2
Sara Romero-Vázquez1Oriol Sibila4
Alfredo Adan1,2Carolina Garcia-Vidal5
Alex Soriano5,6- 1Group of Ocular Inflammation: Clinical and Experimental Studies, Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Barcelona, Spain
- 2Institut Clínic d’Oftalmologia (ICOF), Hospital Clínic, Barcelona, Spain
- 3Statistical Department, Universitat Autònoma de Barcelona, Barcelona, Spain
- 4Respiratory Department, Hospital Clinic of Barcelona-IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain
- 5Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain
- 6CIBERINF, Barcelona, Spain
A corrigendum on
C-reactive protein isoforms as prognostic markers of COVID-19 severity
by Molins B, Figueras-Roca M, Valero O, Llorenç V, Romero-Vázquez S, Sibila O, Adán A, García-Vidal C and Soriano A (2023). Front. Immunol. 13:1105343. doi: 10.3389/fimmu.2022.1105343
In the published article, there was an error in the Funding statement. The first sentence was incorrectly written as “This work was funded by the Ministry of Science and Innovation of Spain, “Instituto de Salud Carlos III”, “Fondo de Investigación Sanitaria” (grant number PI19/00265), and Funds FEDER “Una manera de hacer Europa”. It should appear as “This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/00265 and co-funded by the European Union”. The correct Funding statement appears below.
Funding
This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/00265 and co-funded by the European Union. We are indebted to the Fundació Glòria Soler for its contribution and support to the COVIDBANK of HCB-IDIBAPS. This work was financed by ad hoc patronage funds for research on COVID-19 from donations from citizens and organizations to the Hospital Clínic de Barcelona-Fundació Clínic per a la Recerca Biomèdica.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: C-reactive protein, COVID-19, isoforms, inflammation, prognosis
Citation: Molins B, Figueras-Roca M, Valero O, Llorens V, Romero-Vázquez S, Sibila O, Adan A, Garcia-Vidal C and Soriano A (2024) Corrigendum: C-reactive protein isoforms as prognostic markers of COVID-19 severity. Front. Immunol. 15:1447976. doi: 10.3389/fimmu.2024.1447976
Received: 13 June 2024; Accepted: 13 June 2024;
Published: 21 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, Lausanne, SwitzerlandCopyright © 2024 Molins, Figueras-Roca, Valero, Llorens, Romero-Vázquez, Sibila, Adan, Garcia-Vidal and Soriano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Blanca Molins, bmolins@recerca.clinic.cat